Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 20;23(1):683.
doi: 10.1186/s12885-023-11187-5.

Vaginal microbiome community state types and high-risk human papillomaviruses in cervical precancer and cancer in North-central Nigeria

Jonah Musa  1   2   3 , Mamoudou Maiga  4   5   6 , Stefan J Green  7 , Francis A Magaji  8 , Ali J Maryam  4 , Mark Okolo  9 , Chuwang J Nyam  10   11 , Nanma T Cosmas  9 , Olugbenga A Silas  12 , Godwin E Imade  8   11 , Yinan Zheng  4 , Brian T Joyce  4 , Brehima Diakite  13 , Imran Morhason-Bello  14 , Chad J Achenbach  15   16 , Atiene S Sagay  8 , Innocent A O Ujah  8   17 , Robert L Murphy  14   16 , Lifang Hou  4   5   18 , Supriya Dinesh Mehta  10   19
Affiliations

Vaginal microbiome community state types and high-risk human papillomaviruses in cervical precancer and cancer in North-central Nigeria

Jonah Musa et al. BMC Cancer. .

Abstract

Background: High risk human papillomaviruses (HR-HPV) have a causal role in cervical oncogenesis, and HIV-mediated immune suppression allows HR-HPV to persist. We studied whether vaginal microbiome community state types (CSTs) are associated with high-grade precancer and/or invasive cervical cancer (HSIL/ICC).

Methods: This was a cross-sectional study of adult women with cervical cancer screening (CCS) at the Jos University Teaching Hospital (JUTH) in Jos, Nigeria, between January 2020 and February 2022. Cervical swabs underwent HPV genotyping (Anyplex™ II HPV28). Cervico-vaginal lavage (CVL) sample was collected for 16 S rRNA gene amplicon sequencing. We used multivariable logistic regression modelling to assess associations between CSTs and other factors associated with HSIL/ICC.

Results: We enrolled 155 eligible participants, 151 with microbiome data for this analysis. Women were median age 52 (IQR:43-58), 47.7% HIV positive, and 58.1% with HSIL/ICC. Of the 138 with HPV data, 40.6% were negative for HPV, 10.1% had low-risk HPV, 26.8% had single HR-HPV, and 22.5% had multiple HR-HPV types. The overall prevalence of any HR-HPV type (single and multiple) was 49.3%, with a higher proportion in women with HSIL/ICC (NILM 31.6%, LSIL 46.5%, HSIL 40.8%, and 81.5% ICC; p = 0.007). Women with HIV were more likely to have HSIL/ICC (70.3% vs. 29.7% among women without HIV). In crude and multivariable analysis CST was not associated with cervical pathology (CST-III aOR = 1.13, CST-IV aOR = 1.31). However, in the presence of HR-HPV CST-III (aOR = 6.7) and CST-IV (aOR = 3.6) showed positive association with HSIL/ICC.

Conclusion: Vaginal microbiome CSTs were not significantly associated with HSIL/ICC. Our findings suggest however, that CST could be helpful in identifying women with HSIL/ICC and particularly those with HR-HPV. Characterization of CSTs using point-of-care molecular testing in women with HR-HPV should be studied as an approach to improve early detection and cervical cancer prevention. Future longitudinal research will improve our understanding of the temporal effect of non-optimal CST, HR-HPV, and other factors in cervical cancer development, prevention, and control.

Keywords: Cervical precancer and cancer; HIV; High-risk HPV; Vaginal microbiome.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest to declare.

Figures

Fig. 1
Fig. 1
Frequency distribution of type-specific HPV genotypes at enrollment (HPV-16 is the commonest, then types 56,58, 18, followed by 45, 51, 52, and 53)
See this image and copyright information in PMC

References

    1. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, McAllister DA, Gottlieb SL, Klug SJ, Winkler AS, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161–9. doi: 10.1016/S2214-109X(20)30459-9. - DOI - PMC - PubMed
    1. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health. 2016;4(9):e609–16. doi: 10.1016/S2214-109X(16)30143-7. - DOI - PubMed
    1. Jonah Musa CA, Babafemi Taiwo B, Berzins O, Silas PH, Daru O, Agbaji G, Imade AS, Sagay JA, Idoko, Phyllis J. Kanki and Robert L Murphy: high-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology. Infect Agents Cancer 2014, 9. - PMC - PubMed
    1. Mogtomo ML, Malieugoue LC, Djiepgang C, Wankam M, Moune A, Ngane AN. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infect Agent Cancer. 2009;4:9. doi: 10.1186/1750-9378-4-9. - DOI - PMC - PubMed
    1. Williamson AL. The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa. J Clin Med. 2015;4(4):579–92. doi: 10.3390/jcm4040579. - DOI - PMC - PubMed

MeSH terms